1. Home
  2. KNSA vs CELC Comparison

KNSA vs CELC Comparison

Compare KNSA & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kiniksa Pharmaceuticals Ltd.

KNSA

Kiniksa Pharmaceuticals Ltd.

HOLD

Current Price

$52.46

Market Cap

3.5B

Sector

Health Care

ML Signal

HOLD

Logo Celcuity Inc.

CELC

Celcuity Inc.

HOLD

Current Price

$118.92

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KNSA
CELC
Founded
2015
2011
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5B
3.1B
IPO Year
2018
2017

Fundamental Metrics

Financial Performance
Metric
KNSA
CELC
Price
$52.46
$118.92
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
9
Target Price
$58.43
$112.56
AVG Volume (30 Days)
742.4K
654.3K
Earning Date
04-28-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
225.00
N/A
EPS
0.27
N/A
Revenue
$677,564,000.00
N/A
Revenue This Year
$37.48
N/A
Revenue Next Year
$17.87
$720.19
P/E Ratio
$71.19
N/A
Revenue Growth
60.09
N/A
52 Week Low
$25.71
$9.64
52 Week High
$54.23
$129.09

Technical Indicators

Market Signals
Indicator
KNSA
CELC
Relative Strength Index (RSI) 66.79 50.85
Support Level $40.67 $99.38
Resistance Level N/A N/A
Average True Range (ATR) 2.20 7.17
MACD 0.68 -0.44
Stochastic Oscillator 85.60 54.80

Price Performance

Historical Comparison
KNSA
CELC

About KNSA Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Share on Social Networks: